Background. The multicomponent meningococcal serogroup B vaccine (4CMenB) is an outer membrane vesicle and recombinant protein-based vaccine licensed to protect against serogroup B meningococcal disease. It remains unknown whether this vaccine will prevent carriage or transmission, key aspects in long-term vaccine success and disease eradication.
Infection with Neisseria meningitidis (the meningococcus) can result in a range of diseases with devastatingly high mortality rates despite medical intervention [1] . Meningococcal vaccines using protein conjugates of capsule carbohydrates have shown great success in preventing invasive meningococcal disease worldwide [2] . However, prior to 2014, no vaccines were available to protect against serogroup B meningococci because their capsular antigen cross-reacts with neurological tissues [3] . Therefore, both protein and vesicle-based vaccines have been in development to circumvent this problem and also, ideally, to achieve greater crossgroup protection [4] .
A multicomponent meningococcal serogroup B vaccine (4CMenB) vaccine (Bexsero; GlaxoSmithKline) was licensed and recommended for widespread pediatric use in the United Kingdom and the United States for prevention of group B meningococcal meningitis [5] [6] [7] . The 4CMenB vaccine comprises detergent-extracted outer membrane vesicles (OMVs), which contains the immunodominant protein antigen porin A (PorA), combined with 3 additional recombinant proteins: factor H binding protein (FHbp), neisserial heparin-binding antigen (NHBA), and neisserial adhesin A (NadA) [8] .
As evidenced by the success of the meningococcal group C vaccine, it is clear that achievement of sterilizing immunity is critical in disease control [9] . Ideally, a successful group B meningococcal vaccine will follow in the footsteps of serogroup A and C vaccines, not only by preventing invasive disease but also by reducing community carriage rates via herd protection that prevents and/or accelerates clearance of asymptomatic colonization in the nasopharynx [9] [10] [11] [12] . 4CMenB vaccine efficacy has been difficult to test, because human rates of group B meningococcal carriage are low [13] . Furthermore, owing to the lack of appropriate animal models, it has remained virtually impossible to predict what effect 4CMenB immunization will have on nasopharyngeal carriage. Although a decrease in acute, invasive disease is expected, the full extent of disease reduction and achievement of herd protection will not be revealed until several years of community data is collected.
Although previous models have been proposed [14] [15] [16] [17] , the lack of a robust animal model of nasopharyngeal carriage by a variety of N. meningitidis strains has greatly hindered the study of meningococcal vaccines in development. This challenge is primarily attributable to the exquisite human specificity of N. meningitidis. Recently, we developed a model to overcome this challenge, taking advantage of transgenic mice that express a human mucosal receptor to which the meningococci adhere, the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) [18, 19] . The neisserial opacity-associated (Opa) protein adhesins are well established to bind CEACAMs from humans but not other animals [20] [21] [22] [23] . Importantly, human CEACAM1 (hCEACAM1) transgenic mice express the receptor on the epithelia of the nasopharynx and allow for bacterial attachment and colonization for extended periods [18] . This model provides a unique opportunity to assess the ability of 4CMenB immunization to limit nasopharyngeal colonization. Indeed, in support of the utility of this model in assessing vaccines, the group C meningococcal vaccine-mediated reduction of nasal carriage in humans is recapitulated in the hCEACAM1 mouse infection model [18] . Therefore, data collected using this approach can be inferred to provide insights for the future success of other meningococcal vaccines.
Herein, we determine that the ability of 4CMenB immunization to affect colonization of the hCEACAM1 mice was highly dependent on antigen variant expression by the challenge strain. Notably, this immunity to mucosal challenge did not correlate with serum antibodies levels, since high-titer strain-reactive antibodies were present in all immunized mice. Moreover, the vaccine-induced immunity was protective against invasive challenge by all strains, so humoral protection did not predict mucosal immunity. When considered together, these results suggest that the 4CMenB vaccine will not affect asymptomatic nasopharyngeal carriage by the same spectrum of strains for which it confers protection against invasive meningococcal disease.
MATERIALS AND METHODS

Bacteria Strains
Neisseria meningitidis were routinely grown on gonococcal agar supplemented with IsoVitaleX and VCNT inhibitor (Becton Dickinson) at 37°C in 5% carbon dioxide. Liquid culture was conducted in brain-heart infusion broth at 37°C with shaking. Bacterial strain sources and attributes are described in Table 1 [24] [25] [26] [27] [28] [29] . All media were from Becton Dickinson.
Mouse Infection Studies
Sepsis modeling was performed as described elsewhere [30, 31] . Groups of 5-8 wild-type FvB mice (Charles River) were immunized with 100 μL of either the 4CMenB vaccine (Bexsero) or a control solution of 1 mg/mL aluminum hydroxide (Sigma) adjuvant in sterile phosphate-buffered saline on days 0 and 21. On day 35, mice were inoculated via intraperitoneal injection with approximately 5 x 10 7 colony-forming units (CFUs) of the designated N. meningitidis strain. Mice also received a separate intraperitoneal injection containing 2 mg of iron dextran (Sigma) diluted in sterile phosphate-buffered saline as an iron source to facilitate bacterial replication. Clinical symptoms of infected mice were monitored at least every 12 hours. Mice reaching end point criteria of 20% weight loss or severe clinical symptoms were humanely euthanized.
Intranasal colonization studies were conducted as described by Johswich et al [18] . FvB mice expressing the hCEACAM1 transgene (bred in-house) were immunized on days 0 and 21. On day 35, mice were anesthetized with Isoflurane (Baxter) and inoculated via intranasal instillation with approximately 1 x 10 7 CFUs of the indicated N. meningitidis strain. Mice were euthanized by carbon dioxide asphyxiation 3 days after infection (day 38), and the burden of colonization was assessed after tracheal cannulation and lavage followed by direct swabbing of the nasal passages. Plated samples were enumerated after overnight growth.
All animal experiments were conducted in accordance with the Animal Ethics Review Committee of the University of Toronto, which is subject to the ethical and legal requirements under the province of Ontario's Animals for Research Act and the federal Council on Animal Care.
Whole-Bacteria Enzyme-Linked Immunosorbent Assays
Anti-meningococcal antibodies were measured by whole-bacteria emzyme-linked immunosorbent assay (ELISA), as described elsewhere [18] . Briefly, flat-bottomed 96-well Immuno plates (Nunc) were coated with suspensions of heat-inactivated N. meningitidis, and 50 µL per well of diluted serum was used for primary binding, followed by detection with alkaline phosphatase (AP)-conjugated goat-anti-mouse immunoglobulin G (IgG) Fc(γ) (Jackson Immunoresearch). After addition of BLUEPHOS AP detection substrate (KPL) and stopping of the reaction with AP-Stop solution (KPL), detection occurred at an optical density of 620 nm.
Immunoblot Analysis
Bacterial lysates were resolved on 10% or 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by wet transfer to nitrocellulose. Where indicated, diluted pooled BuFa 02/03 NadA W Beernink et al [28] 2006-093 PorA, NHBA, FHbp B Bettinger et al [29] 2007-015 PorA, NHBA, FHbp B Bettinger et al [29] 2009-149 PorA, FHbp B Bettinger et al [29] Abbreviations: 4CMenB, multicomponent meningococcal serogroup B vaccine; FHbp, factor H binding protein; NadA, neisserial adhesin A; NHBA, neisserial heparin-binding antigen; OMV, outer membrane vesicles; PorA, porin A.
mouse serum samples or monoclonal FHbp-specific antibody was used for primary detection, and detected with appropriate horseradish peroxidase-conjugated secondary antibodies.
Statistical Analyses
Survival curves in the invasive challenge model were compared by means of the log-rank Mantel-Cox test, and mean serum antibody levels from ELISA assays by means of 2-tailed t tests. Differences in colonization burden were assessed using a 2-tailed Mann-Whitney test. All statistical analyses were conducted using GraphPad Prism 6 software (GraphPad); differences were considered statistically significant at P < .05.
RESULTS
Immune Cross-Reactivity Against Diverse N. meningitidis Strains After 4CMenB Vaccination
To determine the potential for the 4CMenB-induced humoral response to cross-react against meningococci that vary in antigen expression, naive mice were immunized with 100 μL of the commercial (Bexsero) preparation or adjuvant control and boosted with the same on day 21. Antibodies recovered from day 35 terminal serum samples or nasal lavage fluid were assessed by means of whole-bacteria ELISA for reactivity against a panel of N. meningitidis strains selected to predominantly match only 1 of the 4 major protein antigens of 4CMenB (PorA, FHbp, NadA, or NHBA) or the OMV, which was prepared from the New Zealand epidemic strain, NZ98/254 (Table 1) . Each strain used is matched with a single vaccine antigen with the exception of strain NZ98/254, which shares PorA, FHbp, and OMV components with the vaccine. Nearly all strains express NHBA; however, extremely low expression levels demonstrated in previous studies suggest little interference in interpretation of data [32] . All mice immunized with 4CMenB had detectable serum and nasal IgG responses against all strains tested (Figure 1 ). By design, the whole-bacteria ELISA will detect all antibody responses generated against the individual strains, including both the specific responses to the protein antigen matches and to any other surface antigen match from the OMV, providing an overview of the overall immune response elicited by immunization. Consistent with this finding, immunoblots of bacterial lysates probed with pooled serum samples from the immunized mice, but not adjuvant control mice confirm that antisera from 4CMenB-immunized mice recognize both shared and discrete proteins expressed by each strain (Figure 1 and data not shown). Multiple bands are not unexpected, given that vaccine OMVs contain many antigenic surface proteins [33] .
Collectively, analysis of serum samples after immunization with 4CMenB showed that antibodies elicited broadly recognize N. meningitidis surface antigens, which suggests that this immune response may provide protection against challenge with these strains. Presence of anti-meningococcal IgG in nasal washes might further allow for local protection in the nasal mucosa.
Correlation Between Serum Antibody Titers and Protection From a Lethal
Dose of N. Meningitidis
To confirm that antibodies generated after 4CMenB immunization were protective, 4CMenB-immunized or adjuvant-immunized control mice were challenged with a lethal dose of N. meningitidis in an invasive disease model [31] . For each of the 5 strains tested, clinical symptoms were fewer and less severe (data not shown), and survival was significantly superior in mice that received the 4CMenB vaccine (Figure 2 ). Together these data support the hypothesis that circulating systemic antibodies are effective at protecting against acute invasive disease for each of these strains. These results are consistent with the findings of others, and together they suggest that immunization with the 4CMenB vaccine will help reduce the incidence and severity of invasive meningococcal disease [32] .
No Correlation Between Serum Antibody Titers and Nasopharyngeal
Colonization Protection
The ability of a vaccine to reduce carriage rates in a population is critical for achievement of herd protection, however the effect of the 4CMenB vaccine on nasal carriage rates remains unknown. In the absence of long-term clinical data, predictions have been hindered by lack of appropriate animal models. We used a transgenic mouse model of nasopharyngeal colonization to gauge the impact of 4CMenB immunization on nasal challenge [18] . Mice received 2 immunizations with 4CMenB or adjuvant, followed by direct intranasal challenge with 1 of the N. meningitidis panel strains.
Mice challenged with N. meningitidis strain NZ98/254 showed a dramatic reduction in both infection rate and bacterial burden of colonization compared with control mice that received adjuvant alone (reduction from 80% to 30% colonized, with 25-fold reduction in the mean number of CFUs recovered [80.6 vs 3.15] from infected mice; Figure 3 ). This suggests that constituents of the OMV, the antigenically dominant protein PorA, the low-expressed FHbp, or some combination of the 3 are protective against nasopharyngeal colonization [32, 34] .
Strain N. meningitidis SK016 matches the vaccine antigen for PorA but differs in strain background and, therefore, the composition of variable outer membrane antigens [35] . After challenge with this strain, no difference was detected in rate of colonization between 4CMenB-immunized and control mice; although the mean CFU count was decreased in the 4CMenB-immunized mice, this difference was not statistically significant (100% vs 90% colonized, mean CFU count, 88.70 vs 27.83). Mice challenged with either NZ98/254 or SK016 showed robust levels of serum IgG against the respective challenge strain and did not show marked differences in the ability of antibodies to recognize the respective challenge strains (Figure 4) . Thus, although it might contribute to protection, PorA itself is insufficient as a vaccine antigen to prevent nasal colonization. Groups of 5-8 mice received 2 immunizations with 4CMenB or adjuvant control followed by an intraperitoneal injection of 5 × 10 7 colony-forming units of the designated challenge strain. Clinical symptoms were monitored every 12 hours, and mice that reached an end point were humanely euthanized. Survival curves are shown depicting mice that received 4CMenB vaccine (black) or adjuvant control (gray). *P < .05 for differences in survival curves (log-rank Mantel-Cox test). Abbreviations: FHbp, factor H binding protein; NadA, neisserial adhesin A; NHBA, neisserial heparin-binding antigen; OMV, outer membrane vesicle; PorA, porin A.
When mice were challenged with strains that matched 4CMenB antigens for only FHbp (strain H44/76) or NHBA (strain S3446), no significant differences in infection rate or burden were detected between mice that received the 4CMenB vaccine and controls that did not [27, 32] . Thus, although the immunized mice have antibodies that effectively protect against invasive challenge (Figures 2 and 4) , their immunity is not sufficient to restrict colonization at the mucosal surfaces.
Challenge with the N. meningitidis strain BuFa 02/03, which matches the 4CMenB antigen NadA [28, 36] , revealed a significant reduction in rate and burden of colonization in 4CMenB-immunized mice compared with adjuvant-immunized controls (Figure 3 ). This finding is notable because this strain, unlike all others tested here, is from group W and not group B; in addition to suggesting that immunity elicited against NadA may suppress colonization, this finding supports the potential for wider (non-group B) cross-protection from the 4CMenB vaccine, as has been suggested elsewhere [37, 38] .
Data collected from whole-bacteria immunoassays demonstrate that antibodies generated after 4CMenB immunization recognize components of each bacterial strain that we used for challenge and that antibodies are detectable at the mucosal site (Figure 1 ). To address whether the absence of mucosal protection resulted from an absence of antibodies to the targeted antigen, we selected the FHbp for further analysis. Immunoblots probing Escherichia coli that express recombinant meningococcal FHbp or control strains containing an empty vector demonstrate that the 4CMenB-immunized mice had generated antibodies that react with the N. meningitidis FHbp ( Figure 5 ). Furthermore, immunoblots using an antibody specific to antiFHbp revealed that bacteria used for challenge were expressing FHbp at the time of infection (data not shown). These findings suggest that the reason for lack of nasal protection after immunization is neither lack of antigen expression on the surface of bacteria used for the inoculum nor lack of antibodies specific to the vaccine antigen.
To this point, strains had been selected to match only select vaccine antigens, to directly assess how each contributes to protection. However, it is likely that strains circulating in the population will vary greatly in the combination and expression of vaccine antigens. Thus, 3 Canadian clinical isolates (2006-093, 2007-015, and 2009-149) were chosen for further analysis based on expression of 2 or more vaccine antigens by meningococcal antigen typing system (MATS) analysis (Table 1 ) [29] . After vaccination, colonization was significantly reduced for 2 of 3 strains, 2007-015 (89% vs 0% colonized; mean CFU count, 36.67 vs 0) and 2009-149 (all mice colonized; mean CFU count, 150.14 vs 11.57); the third stain, 2006-093, displayed a decreased rate of colonization, but the difference was not statistically significant (63% vs 25% colonized; mean CFU count, Figure 3 . Protection afforded against nasopharyngeal carriage is strain specific. Two immunizations with multicomponent meningococcal serogroup B (4CMenB) vaccine or adjuvant control were administered to mice before intranasal challenge with 1 × 10 7 colony-forming units (CFUs) of the noted challenge strains. Three days after infection the bacterial load was determined, and the CFUs recovered from mice that received 4CMenB (black) or adjuvant control (gray) are shown. Dashed lines represent the lower limit of detection; bars, group medians. *P < .05 for differences in group mean CFU counts (2-tailed Mann-Whitney test). Abbreviations: FHbp, factor H binding protein; NadA, neisserial adhesin A; NHBA, neisserial heparin-binding antigen; NS, not significant; OMV, outer membrane vesicle; PorA, porin A. Figure 6 ). Taken together, these findings suggest that combinations of antigen matches may have an additive effect and that vaccination may reduce carriage of some strains circulating in the population.
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DISCUSSION
The licensure of the 4CMenB vaccine [5] [6] [7] represents the successful culmination of a sustained effort to develop a vaccine targeting group B meningococci and provides an important new tool to combat this dangerous pathogen [1] . As discussed below, this vaccine elicits bactericidal antibodies specific for strains expressing sufficient surface densities of protein variants that cross-react against the vaccine antigens. However, owing to the lack of animal models for colonization available for preclinical testing and the absence of any correlates of protection for mucosal immunity against the meningococci, the 4CMenB vaccine is being administered clinically with no predictions as to the potential impact on asymptomatic carriage. In fact, to date, only 1 study has attempted to address the issue of whether 4CMenB immunization might influence asymptomatic carriage [13] . Although a modest decrease in meningococcal carriage was seen across all strains in this study, there was little evidence of an effect on group B strains. However, the results from this clinical study are difficult to interpret owing to the low rate of newly acquired meningococcal carriage events over the course of the analysis, suggesting that clear data may not be possible without large-scale, multiyear surveillance programs after widespread immunization.
Herein, we capitalize on our hCEACAM1-expressing transgenic mouse model of N. meningitidis asymptomatic colonization to address this important question systematically [18] . Our data suggest that although 4CMenB immunization can substantially reduce morbidity and mortality rates in an invasive model of disease, it had a far less predictable impact on preventing carriage, and this depends on which and how many of the vaccine antigens are shared by the infecting strain.
Immunization with 4CMenB was strongly protective against both invasive and nasal challenge with strain NZ98/254. Because the OMVs of the vaccine are derived from this strain [4] , the immune serum can be expected to target multiple antigens on the surface of these bacteria. This seems consistent with an earlier observation that native OMVs can themselves be protective against meningococcal nasal colonization by the OMV-producing strain [39] . Given that PorA is considered the immunodominant component of OMV vaccines, we were surprised to observe that a response against this antigen alone was insufficient to confer protection against mucosal infection, indicated by immunized mice being fully susceptible to nasal challenge with a PorA-matched strain (SK016).
It has been demonstrated that immunization with intact FHbp can allow this antigen to complex with the endogenous human factor H and that this can dampen the FHbp-specific immune response [35] . It is important to note that the neisserial FHbp does not interact with nonhuman factor H [40] , so these effects are not confounding in this study. However, even without this negative effect, immunization with 4CMenB did not confer protection against nasal challenge with a strain matching the FHbp. Of note, the other available group B meningitis vaccine, licensed in the United States in 2014 (Trumenba; Pfizer), contains 2 lipidated FHbp variants as the only meningococcal-derived antigens [41] . Although this was not tested in the current study, our data would predict that a factor H binding protein-based vaccine will not protect against asymptomatic meningococcal colonization, but this remains to be tested.
In the present study, 4CMenB protected against invasive challenge by a strain selected only to match the vaccine for NHBA (strain S3446), but immunization did not prevent nasal carriage. NHBA was previously shown to be widely present across group B meningococcal strains and to elicit NHBA-specific antibodies [32] . Although frequently dismissed owing to the low expression levels of NHBA in many strains, cooperation of NHBAspecific antibodies with other anti-meningococcal antibodies can occur. Therefore, a possible contribution of this antigen to immunity should not be overlooked-for example, in the protection observed here against strain NZ98/254 [42] . 4CMenB provided protection against nasal colonization with the group W strain, BuFa 02/03, which matched the vaccine antigen NadA. This neisserial adhesin is known to be important for attachment to epithelial cells [43] . Although 4CMenB antigens were chosen through a reverse vaccinology approach, there is clear rationale for targeting bacterial adhesins in vaccines. It is interesting to speculate whether antibodies generated against NadA are able to block initial attachment and adhesion, as this would certainly be expected to impede nasal colonization. One must keep in perspective, however, that even with the promising protection demonstrated here, only half of N. meningitidis strains are predicted to express NadA [44] . Two immunizations with 4CMenB or adjuvant control were administered to mice before intranasal challenge with 1 × 10 7 colony-forming units (CFUs) of the noted challenge strains. Three days after infection, the bacterial load was quantified as CFUs recovered from mice that received 4CMenB vaccine (black) or adjuvant control (gray). Dashed lines represent lower limit of detection; bars, group medians. *P < .05 for that differences in group mean CFU counts (2-tailed Mann-Whitney test). Abbreviations: FHbp, factor H binding protein; NHBA, neisserial heparin-binding antigen; NS, not significant; PorA, porin A.
The original strains used in this study were deliberately chosen to predominantly match single components of the 4CMenB vaccine. This allowed for differentiation of protein antigens that were contributing to protection in a nasal carriage model. Our data do not rule out additional antigenic matches to the OMV, although protection afforded by OMV-based vaccines have been previously shown to be highly strain specific [45, 46] . Instead, this strategy effectively tests the limits of this vaccine's potential to protect, because it highlights the fact that antigen cross-reactivity does not necessarily confer mucosal protection. In particular, though the single antigens were each able to confer effective protection in the invasive challenge model, the individual protein matches were largely unsuccessful at carriage protection. Given that expression levels of surface proteins, including those studied herein, can vary greatly between strains and growth conditions, future studies may reveal that expression patterns of surface proteins during mucosal colonization versus invasive infection contribute to the differences seen in protection [47, 48] .
We tested low-passage, MATS-characterized clinical isolates to address whether strains matching >1 vaccine antigen will have an additive effect and/or whether different combinations will reveal synergistic protection where single antigens have fallen short [42] . These points are essential for modeling vaccine impact, because the strength of antigen matches between the vaccine and endemic or epidemic strains will undoubtedly be influenced by geography and change over time. Each of the 3 strains tested showed a reduction in carriage and/or bacterial burden, suggesting that increasing antigen matches decreases the likelihood of colonization and that immunization has the potential to offer herd protection against some strains.
Together, our findings suggest that the humoral response induced by 4CMenB cannot be used to predict its impact on asymptomatic carriage by N. meningitidis, because immunization reduced colonization by only 1 of the 4 single antigen-matched strains tested, despite the presence of antibody effective at protecting against invasive challenge by these strains. It is important to reiterate that this does not reduce the utility of this vaccine for its intended purpose of protecting against meningococcal disease in immunized individuals. However, if the findings from our study are borne out in humans, then we may expect the vaccine to have either only modest or no detectable long-term effects on carriage, because, although certain strains may be lost from the population, it seems feasible that those that are not restricted would replace them [49, 50] . Such an absence of herd protection has important implications for modeling the benefit of this vaccine and, perhaps more importantly, precludes our ability to use it to eliminate N. meningitidis from its nasal reservoir.
Notes
